Poolbeg Pharma (AIM:POLB) has bagged Orphan Drug Designation from the FDA for POLB 001, targeting cancer therapy-related CRS. The status brings key incentives and boosts commercial potential ahead of clinical trials later this year.
Faron Pharmaceuticals (AIM:FARN) says new lab data shows its drug bexmarilimab could make blood cancer treatments work better. Early results showed stronger immune response and lower leukaemia cell viability when combined with existing therapies.
Cordiant Digital Infrastructure (LSE:CORD) has announced the expansion of its Czech portfolio company, CRA, which increased the scope of its DAB+ network. It's also ramping up data centre capacity in Prague amid rising demand.
Inspired PLC (AIM:INSE) says it’s ready to support a £129 million takeover bid from HGGC, trumping a lower rival offer. Talks are ongoing, but the board calls the US private equity proposal “superior” and could back it soon.
Imaging Biometrics has officially changed its name from IQ-AI Ltd, with ticker symbol now IBAI on the London Stock Exchange. Shareholders don’t need to do anything, and a new website is on the way.
Follow us and subscribe on YouTube, our social channels and on proactiveinvestors.co.uk.
